Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL

David O’Connor, Jose Espejo Valle-Inclán, Lucia Conde, Gianna Bloye, Sunniyat Rahman, Joana R. Costa, Jack Bartram, Stuart Adams, Gary Wright, Hillary Elrick, Kerry Wall, Sara Dyer, Christopher Howell, Galina Jigoulina, Javier Herrero, Isidro Cortes-Ciriano, Anthony V. Moorman, Marc R. Mansour

Blood (2024) 143 (10): 933–937.

https://doi.org/10.1182/blood.2023021906

Published: 2024

Includes: Supplemental data

Journal Articles

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2023-186318

Published: 2023

Journal Articles

The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

David O'Connor, Jonas Demeulemeester, Lucia Conde, Amy A. Kirkwood, Kent Fung, Foteini Papaleonidopoulou, Gianna Bloye, Nadine Farah, Sunniyat Rahman, Jeremy Hancock, Caroline Bateman, Sarah Inglott, Jon Mee, Javier Herrero, Peter Van Loo, Anthony V. Moorman, Ajay Vora, Marc R. Mansour

Blood (2022) 140 (Supplement 1): 1720–1721.

https://doi.org/10.1182/blood-2022-165308

Published: 2022

Journal Articles

The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL

Joana R Costa, David O'Connor, Nurkaiyisah Anuar, Sunniyat Rahman, Nivedita Singh, Zhaodong China, Tanya Rapoz-D'Silva, Yang Li, Kent Fung, Sara Hyseni, Stephen Henderson, George Morrow, Yanping Guo, Javier Herrero, Richard Jenner, Dennis Keppei, A. Thomas Look, Marc R. Mansour

Blood (2022) 140 (Supplement 1): 3046–3047.

https://doi.org/10.1182/blood-2022-166396

Published: 2022

Journal Articles

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Blood (2022) 140 (Supplement 1): 10106–10107.

https://doi.org/10.1182/blood-2022-169882

Published: 2022

Journal Articles

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Blood (2018) 132 (20): 2154–2165.

https://doi.org/10.1182/blood-2018-05-849893

Published: 2018

Includes: Supplemental data

Journal Articles

A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction As a Developmental Susceptibility to ETV6-RUNX1

Simon E Richardson, MA, MD PhD MRCP, FRPATH, Charlotta Boiers, MDPhD, Alya Zriwil, PhD, Emma Laycock, Virginia A Turati, DPhil, John Brown, PhD, Jason Wray, PhD, Chela James, PhD, Dapeng Wang, PhD, Javier Herrero, PhD, Ewa Sitnicka, PhD, Stefan Karlsson, MD, Andrew J.H. Smith, PhD, Sten Eirik Jacobsen, MDPhD, Tariq Enver, PhD

Blood (2017) 130 (Supplement 1): 1218.

https://doi.org/10.1182/blood.V130.Suppl_1.1218.1218

Published: 2017

Journal Articles

Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL

Theresa E. Leon, PhD MSc, BSc, Tanya Rapoz-D'Silva, BSc, MSc, Sunniyat Rahman, MBiochem, DIC, PhD, Michael Magnussen, BSc, MSc, Nadine Farah, MBBChir, MA, MRCP, FRCPath, Jose A. Guerra-Assunção, BSc, PhD, Rajeev Gupta, MB.ChB, PhD FRCP, FRCPath, Elisabeth P. Nacheva, MD PhD, Javier Herrero, PhD, David C. Linch, FRCP, Marc R. Mansour, MD PhD FRCPath

Blood (2017) 130 (Supplement 1): 1325.

https://doi.org/10.1182/blood.V130.Suppl_1.1325.1325

Published: 2017

Journal Articles

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Blood (2017) 130 (Supplement 1): 267.

https://doi.org/10.1182/blood.V130.Suppl_1.267.267

Published: 2017

Journal Articles

Single-Cell Analysis of Clonal Dynamics in Childhood ALL Reveals a Key Role for Transcriptional Intratumor Heterogeneity in Driving Resistance to Chemotherapy

Virginia A Turati, PhD, José Afonso Guerra-Assunção, PhD, John C Ambrose, PhD, John Brown, PhD, Mike Hubank, PhD, Alex Hobbs, PhD, Mark Lynch, PhD, Bernadett Gaal, PhD, Sarah Inglott, Lucia Conde, PhD, Simon Richardson, MD PhD, Javier Herrero, PhD, Sten Eirik Jacobsen, MD PhD, Tariq Enver, PhD

Blood (2016) 128 (22): 606.

https://doi.org/10.1182/blood.V128.22.606.606

Published: 2016

NARROW

Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction As a Developmental Susceptibility to ETV6-RUNX1

Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Single-Cell Analysis of Clonal Dynamics in Childhood ALL Reveals a Key Role for Transcriptional Intratumor Heterogeneity in Driving Resistance to Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only